Benign prostatic hyperplasia/urinary retention:
Indications for: FLOMAX
Benign prostatic hyperplasia (BPH).
Adult Dosage:
Swallow whole. Take ½ hr after same meal of each day. Initially 0.4mg once daily; may increase to 0.8mg once daily after 2–4 weeks if response is inadequate. If therapy is interrupted, resume at 0.4mg once daily and retitrate.
Children Dosage:
Not applicable.
FLOMAX Warnings/Precautions:
Rule out prostate cancer. Sulfa allergy. Syncope. End-stage renal disease. Severe hepatic impairment. Cataract or glaucoma surgery: do not initiate therapy (possible Intraoperative Floppy Iris Syndrome). Not for use in women.
FLOMAX Classification:
Alpha-1 blocker.
FLOMAX Interactions:
Do not use with other α-blockers or strong CYP3A4 inhibitors (eg, ketoconazole). Caution with concomitant moderate CYP3A4 inhibitors (eg, erythromycin), moderate or strong CYP2D6 inhibitors (eg, paroxetine, terbinafine), or CYP2D6 poor metabolizers (esp. with tamsulosin >0.4mg/day). Caution with concomitant cimetidine (esp. with tamsulosin >0.4mg/day) or warfarin. Symptomatic hypotension with concomitant PDE5 inhibitors.
Adverse Reactions:
Headache, abnormal ejaculation, dizziness, rhinitis, infection, asthenia, back pain, diarrhea, pharyngitis, chest pain, nausea, tooth disorder, blurred vision, cough, somnolence, sinusitis, libido decreased, insomnia; rare: priapism.
Drug Elimination:
Renal (76%), fecal (21%). Half-life: 9–13 hours.
Generic Drug Availability:
YES
How Supplied:
Caps—100
